Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271230 · ClinicalTrials.gov registry record · Phase 3
Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure
A Phase 3 study of Heart Failure, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 25,871
- Enrollment target
- 1
- Study location
NCT02271230 is a Phase 3 study of Heart Failure that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25,871 participants, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1204% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02271230, a Phase 3 study of Heart Failure, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25,871 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether an intervention with vitamin D or fish oil supplements can reduce the risk of heart failure among adult men and women during a follow up period of up to five years (starting from the time of randomization into the parent VITAL trial). The investigators hypotheses are that both vitamin D and fish oil supplements will each reduce the risk of heart failure.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Vitamin D and fish oil
- DIETARY_SUPPLEMENT Fish oil (EPA/DHA) alone
- DRUG Vitamin D alone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,871 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271230
The ClinicalTrials.gov registry entry for NCT02271230 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25,871 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1204% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02271230 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02271230 about?
NCT02271230 is a clinical study titled "Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure". This study will examine whether an intervention with vitamin D or fish oil supplements can reduce the risk of heart failure among adult men and women during a follow up period of up to five years (starting from the time of randomization into the parent VITAL trial). The investigators hypotheses are ...
What is the current status of trial NCT02271230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25,871 participants. The study started on 2014-08. Estimated completion is 2019-12.
What conditions does trial NCT02271230 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT02271230?
The interventions under investigation include: Placebo (OTHER), Vitamin D and fish oil (DRUG), Fish oil (EPA/DHA) alone (DIETARY_SUPPLEMENT), Vitamin D alone (DRUG).
Who is sponsoring clinical trial NCT02271230?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02271230 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.